{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-278810","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.573243+00:00","generated_at":"2026-05-16T20:19:10.606808+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027","bullets":["Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.","Cash and marketable securities $161.9M; cash runway into first half 2027.","Phase 3 CoMpass trial in early choroidal melanoma: enrollment completion expected 2026, topline data Q4 2027.","Phase 1b/2 NMIBC trial on track for initial data mid-2026; immune profiling shows cold-to-hot tumor conversion.","First patient dosed in Phase 2 choroidal metastases trial; entry criteria expanded to include all solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-278810","json":"https://secwatch.observer/filing/0001193125-25-278810.json","markdown":"https://secwatch.observer/filing/0001193125-25-278810.md","text":"https://secwatch.observer/filing/0001193125-25-278810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/0001193125-25-278810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/aura-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:19:10.606808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}